J. Lipid Res. Did you know there is a large type edition? Click here.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1194/jlr.M400239-JLR200 on August 16, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M400239-JLR200v1
45/11/2000    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bellamine, A.
Right arrow Articles by Waterman, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bellamine, A.
Right arrow Articles by Waterman, M. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 45, 2000-2007, November 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology

Aouatef Bellamine1, Galina I. Lepesheva and Michael R. Waterman

Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232-0146

1 To whom correspondence should be addressed. e-mail: aouatef.bellamine{at}vanderbilt.edu

14{alpha}-Demethylase (CYP51) is a key enzyme in all sterol biosynthetic pathways (animals, fungi, plants, protists, and some bacteria), catalyzing the removal of the C-14 methyl group following cyclization of squalene. Based on mutations found in CYP51 genes from Candida albicans azole-resistant isolates obtained after fluconazole treatment of fungal infections, and using site-directed mutagenesis, we have found that fluconazole binding and substrate metabolism vary among three different CYP51 isoforms: human, fungal, and mycobacterial. In C. albicans, the Y132H mutant from isolates shows no effect on fluconazole binding, whereas the F145L mutant results in a 5-fold increase in its IC50 for fluconazole, suggesting that F145 (conserved only in fungal 14{alpha}-demethylases) interacts with this azole. In C. albicans, F145L accounts, in part, for the difference in fluconazole sensitivity reported between mammals and fungi, providing a basis for treatment of fungal infections. The C. albicans Y132H and human Y145H CYP51 mutants show essentially no effect on substrate metabolism, but the Mycobacterium tuberculosis F89H CYP51 mutant loses both its substrate binding and metabolism.

Because these three residues align in the three isoforms, the results indicate that their active sites contain important structural differences, and further emphasize that fluconazole and substrate binding are uncoupled properties.

Abbreviations: 14DM/CYP51, cytochrome P450 sterol 14{alpha}-demethylase; 24M-DHL, 24-methylene dihydrolanosterol; ATCC, American Type Culture Collection; CA, Candida albicans; DHL, 24,25-dihydrolanosterol; DLPC, dilauryl-L-{alpha}-phosphatidylcholine; H, human; MT, Mycobacterium tuberculosis

Supplementary key words Candida albicans, human • inhibitor binding • Mycobacterium tuberculosis • substrate metabolism


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Antimicrob. Agents Chemother.Home page
J. E. Parker, M. Merkamm, N. J. Manning, D. Pompon, S. L. Kelly, and D. E. Kelly
Differential Azole Antifungal Efficacies Contrasted Using a Saccharomyces cerevisiae Strain Humanized for Sterol 14{alpha}-Demethylase at the Homologous Locus
Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3597 - 3603.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. N. Eddine, J. P. von Kries, M. V. Podust, T. Warrier, S. H. E. Kaufmann, and L. M. Podust
X-ray Structure of 4,4'-Dihydroxybenzophenone Mimicking Sterol Substrate in the Active Site of Sterol 14{alpha}-Demethylase (CYP51)
J. Biol. Chem., May 30, 2008; 283(22): 15152 - 15159.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
M. Kudo, M. Ohi, Y. Aoyama, Y. Nitahara, S.-K. Chung, and Y. Yoshida
Effects of Y132H and F145L Substitutions on the Activity, Azole Resistance and Spectral Properties of Candida albicans Sterol 14-Demethylase P450 (CYP51): A Live Example Showing the Selection of Altered P450 through Interaction with Environmental Compounds
J. Biochem., May 1, 2005; 137(5): 625 - 632.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Matsuura, S. Yoshioka, T. Tosha, H. Hori, K. Ishimori, T. Kitagawa, I. Morishima, N. Kagawa, and M. R. Waterman
Structural Diversities of Active Site in Clinical Azole-bound Forms between Sterol 14{alpha}-Demethylases (CYP51s) from Human and Mycobacterium tuberculosis
J. Biol. Chem., March 11, 2005; 280(10): 9088 - 9096.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.